HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
GROUND: Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS: Data from a prospective cohort of HIV-infected patients (the HIV Outpatient Study) were used in the analysis. We analysed the frequency with which patients were prescribed any non-nucleoside reverse transcriptase inhibitor after identification of the K103N mutation in reverse transcriptase and the frequency of prescription of nelfinavir after identification of the D30N mutation in HIV protease; the short-term impact of this action on HIV viral load and CD4+ T-cell count was assessed. RESULTS: Among 441 patients demonstrating either mutation, 18% who were taking the resistant antiretroviral at the time of the test were continued on the medication for >6 months after this finding. In 33% of these instances, prescribers reported these actions
Related Questions
- How do I know the improvement in the conversion rate of my E-mail campaign is due to your MultiVariate Testing System rather than changes in the market conditions or the external environment?
- How will my business be affected by the Consumer Product Safety Improvement Acts compliance and testing requirements?
- What is Genotypic Resistance Testing?
